Standout Papers

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cel... 2018 2026 2020 2023 444
  1. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial (2018)
    Philippe Armand, Andreas Engert et al. Journal of Clinical Oncology

Immediate Impact

1 by Nobel laureates 5 from Science/Nature 64 standout
Sub-graph 1 of 21

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
CAR T Cells and T-Cell Therapies for Cancer
2024 Standout
1 intermediate paper

Works of Jonathon B. Cohen being referenced

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
2019
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
2019

Author Peers

Author Last Decade Papers Cites
Jonathon B. Cohen 1657 1593 693 131 2.3k
Graham P. Collins 1513 1586 653 159 2.6k
Krimo Bouabdallah 1411 1112 774 117 2.0k
Kay M. Ristow 1782 1615 477 76 2.8k
Rémy Gressin 1674 1171 852 109 2.5k
Tatyana Feldman 1462 1236 408 154 2.0k
José Rodríguez 1674 1152 527 64 2.0k
Hervé Ghesquières 2024 1496 809 189 2.8k
Carlo Visco 1485 1026 1081 107 2.3k
R. Gregory Bociek 1635 1286 901 119 2.8k
Carla Casulo 1227 1030 527 94 1.8k

All Works

Loading papers...

Rankless by CCL
2026